RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on March 7, 2011 for ...
Bausch Health, its Salix business unit, and Salix’s licensor Alfasigma, have agreed to resolve outstanding intellectual property disputes with Sun Pharmaceuticals regarding Xifaxan (rifaximin) 200-mg ...
XIFAXAN 550 mg Tablets Offer First Clinical Treatment Option in the United States for Patients with Overt HE in More Than 30 Years RALEIGH, NC, March 24, 2010 - Salix Pharmaceuticals, Ltd.
LAVAL, Quebec, May 27, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received ...
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that Dr. Anthony Lembo of Beth Israel Deaconess Medical Center will present the results of TARGET 3 in a ...
Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of ...
With the resubmitted sNDA being treated as a class 2 response, a decision from the FDA regarding the approval status of the drug should be out by Feb 28, 2015. We remind investors that Salix had ...
Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback